SOURCE: Trinity Biotech

September 07, 2005 07:29 ET

Trinity Biotech Directors Purchase Shares in the Company

DUBLIN, IRELAND -- (MARKET WIRE) -- September 7, 2005 --Trinity Biotech plc (NASDAQ: TRIB) (ISE: TRIB.I), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced that members of its board of directors acquired a total of 4,501,675 Ordinary Shares in the company by purchasing TRIB stock on the open market and exercising share options.

The Company reported that Chairman and CEO Ronan O' Caoimh purchased 1,750,800 shares in the open market and exercised 1,070,000 options, President Brendan Farrell purchased 10,000 shares and exercised 526,875 options, COO Jim Walsh purchased 184,000 shares and exercised 750,000 options, CFO Rory Nealon exercised 200,000 options and non-executive director Denis Burger purchased 10,000 shares.

Ronan O'Caoimh, Trinity Biotech CEO, commented, "These transactions reflect the confidence and belief that the senior executives and Board of the Company have in the future of Trinity Biotech."

Trinity Biotech also announces that Brendan Farrell, President, will be speaking at the Roth Capital Partners New York conference today at 8am E.S.T. The event will be webcast and can be accessed on

Trinity Biotech develops, acquires, manufactures and markets over 500 diagnostic products for the point-of-care and clinical laboratory segments of the diagnostic market. The broad line of test kits are used to detect infectious diseases, sexually transmitted diseases, blood coagulation disorders, and autoimmune diseases. Trinity Biotech sells worldwide in over 80 countries through its own salesforce and a network of international distributors and strategic partners.

Trinity Biotech trades its Ordinary Shares on the Irish Stock Exchange and ADR's on Nasdaq. Each ADR represents four Ordinary Shares. For further information please see the company's website:

Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.

Contact Information

  • Contact :
    Trinity Biotech plc
    Rory Nealon
    E-mail: Email Contact